Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award
BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 “Best CEOs.”
“What makes Comparably awards so meaningful is that they are based exclusively on employee feedback,” said Elisabeth Colunio, Vice President of Human Resources. “We are thrilled but not surprised to see John recognized as a 2021 Best CEO. John is an emotionally intelligent, driven, and experienced leader focused on progressing scientific accomplishments within a collaborative and respectful culture.”
A leading workplace culture and compensation monitoring site, Comparably evaluates companies based on sentiment ratings anonymously provided by employees about their workplaces. 70,000 companies were considered for inclusion in Comparably’s annual rankings.
The Best CEO Awards are derived from nationwide sentiment ratings provided by employees who anonymously rated their CEOs on during a 12-month period (November 26, 2020-November 26, 2021). The award is based on verified employee reviews and compares CEOs managing companies of the same size across the United States. Sensei’s ranking places it in the top 5% of all 70,000 companies on Comparably.
About Sensei Biotherapeutics
Sensei Biotherapeutics is a biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer. Sensei has developed two unique approaches – its TMAb™ (Tumor Microenvironment Activated biologics) platform, comprising unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment, and its ImmunoPhage™ platform that leverages bacteriophage to fully engage the immune system. Using its TMAb platform, the company has developed SNS-101, an antibody-based therapeutic in lead generation targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). Using the ImmunoPhage platform, Sensei is developing a library of ImmunoPhage, called Phortress™, with multiple tumor-associated antigens to create a personalized, yet off-the-shelf cocktail approach for treating cancer patients. The platform is designed to enable efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. SNS-401-NG is an ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
Investor Contact:
Erin Colgan
SVP, Finance and Administration
Sensei Biotherapeutics
ecolgan@senseibio.com
